Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin

Biomaterials

Volumn 35, Issue 37, 2014, Pages 9877-9887

  Qiu, Lipeng ^a,b   Qiao, Mingxi ^b   Chen, Qing ^b   Tian, Chenmin ^c   Long, Miaomiao ^b   Wang, Mingyue ^b   Li, Zhen ^b   Hu, Wen ^c   Li, Gang ^b   Cheng, Liang ^c   Cheng, Lifang ^c   Hu, Haiyang ^b   Zhao, Xiuli ^b   Chen, Dawei ^b,c  

^a JIANGNAN UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

Copolymer micelles; D tocopheryl polyethylene glycol succinate; Hyaluronic acid; Multidrug resistance; P glycoprotein; PH sensitive

Indexed keywords

ACID RESISTANCE; AMINO ACIDS; CELL MEMBRANES; COPOLYMERS; CYTOLOGY; GLYCOPROTEINS; LOADING; MAGNESIUM PRINTING PLATES; MICELLES; MITOCHONDRIA; PH SENSORS; POLYETHYLENE GLYCOLS; POLYETHYLENES; TUMORS;

COPOLYMER MICELLES; EXPRESSION LEVELS; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; PH SENSITIVE; POLIES (LHISTIDINE); UNIMODAL SIZE DISTRIBUTION;

HYALURONIC ACID;

ADENOSINE TRIPHOSPHATE; COPOLYMER; DEXTRO ALPHA TOCOPHERYL POLETHYLENE GLYCOL 2000; DOXORUBICIN; DRUG CARRIER; HYALURONIC ACID DERIVATIVE; HYALURONIC ACID G POLY(LEVO HISTIDINE); MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; ANTINEOPLASTIC ANTIBIOTIC; DELAYED RELEASE FORMULATION; HISTIDINE; HYALURONIC ACID; MACROGOL DERIVATIVE; MICELLE; POLYHISTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CELL PH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENDOCYTOSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MEASUREMENT PRECISION; MICELLE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARTICLE SIZE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTON TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NUDE MOUSE; PHARMACOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTIDINE; HUMANS; HYALURONIC ACID; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; MICELLES; P-GLYCOPROTEINS; POLYETHYLENE GLYCOLS; VITAMIN E;

EID: 84907272782     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.08.008     Document Type: Article

References (54)

1. Khasraw M., Bell R., Dang C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 2012, 21:142-149.
2. Vijayaraghavalu S., Dermawan J.K., Cheriyath V., Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol Pharm 2012, 10:337-352.
3. Hu C.M., Zhang L.F. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012, 83:1104-1111.
4. Kievit F.M., Wang F.Y., Fang C., Mok H., Wang K., Silber J.R., et al. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J Control Release 2011, 152:76-83.
5. Stein W., Bates S., Fojo T. Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr Drug Targets 2004, 5:333-346.
6. Klappe K., Hummel I., Hoekstra D., Kok J.W. Lipid dependence of ABC transporter localization and function. Chem Phys Lipids 2009, 161:57-64.
7. Lee E.S., Gao Z., Kim D., Park K., Kwon I.C., Bae Y.H. Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance. J Control Release 2008, 129:228-236.
8. ® copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 2010, 31:2371-2379.
9. Kim D., Lee E.S., Oh K.T., Gao Z.G., Bae Y.H. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 2008, 4:2043-2050.
10. Xiao L., Xiong X.Q., Sun X.H., Zhu Y.H., Yang H., Chen H.B., et al. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials 2011, 32:5148-5157.
11. Bansal T., Akhtar N., Jaggi M., Khar R.K., Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009, 14:1067-1074.
12. Yin Q., Shen J., Zhang Z., Yu H., Li Y. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Adv Drug Deliv Rev 2013, 65:1699-1715.
13. ® P85 unimers. Biomaterials 2013, 34:9602-9614.
14. Zhang Z., Tan S., Feng S.S. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012, 33:4889-4906.
15. Wang J.L., Sun J., Chen Q., Gao Y., Li L., Li H., et al. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials 2012, 33:6877-6888.
16. Tang J., Fu Q., Wang Y., Racette K., Wang D., Liu F. Vitamin E reverses multidrug resistance in vitro and in vivo. Cancer Lett 2013, 336:149-157.
17. Collnot E.M., Baldes C., Wempe M.F., Kappl R., Hüttermann J., Hyatt J.A., et al. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 2007, 4:465-474.
18. Zhang Z., Lee S.H., Gan C.W., Feng S.S. In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res 2008, 25:1925-1935.
19. Prashant C., Dipak M., Yang C.T., Chuang K.H., Jun D., Feng S.S. Superparamagnetic iron oxide-loaded poly(lactic acid)-d-α-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent. Biomaterials 2010, 31:5588-5597.
20. Shen J., Yin Q., Chen L.L., Zhang Z.W., Li Y.P. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 2012, 33:8613-8624.
21. Huang L.Q., Chen H.B., Zheng Y., Song X.S., Liu R.Y., Liu K.X., et al. Nanoformulation of d-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy. Integr Biol 2011, 3:951-1054.
22. Iqbal J., Hombach J., Matuszczak B., Bernkop-Schnürch A. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J Control Release 2010, 147:62-69.
23. Wang Y., Guo M., Lu Y., Ding L.Y., Ron W.T., Liu Y.Q., et al. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly (lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro. Nanotechnology 2012, 23:495103.
24. Zhao H., Yung L.Y.L. Addition of TPGS to folate-conjugated polymer micelles for selective tumor targeting. J Biomed Mater Res A 2009, 91:505-518.
25. 2k) micelles for targeted and synergistic chemotherapy. Biomaterials 2011, 32:4058-4066.
26. Prestwich G.D. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. J Control Release 2011, 155:193-199.
27. Choi K.Y., Yoon H.Y., Kim J.H., Bae S.M., Park R.W., Kang Y.M., et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 2011, 5:8591-8599.
28. Lee E.S., Shin H.J., Na K., Bae Y.H. Poly(l-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release 2003, 90:363-374.
29. Qiu L., Li Z., Qiao M., Long M., Wang M., Zhang X., et al. Self-assembled pH-responsive hyaluronic acid-g-poly (l-histidine) copolymer micelles for targeted intracellular delivery of doxorubicin. Acta Biomater 2013, 10:2024-2035.
30. Liu Y., Sun J., Cao W., Yang J., Lian H., Li X., et al. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm 2011, 421:160-169.
31. Zhu S., Wonganan P., Lansakara D.S., O'Mary H.L., Li Y., Cui Z. The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression. Biomaterials 2012, 34:2327-2339.
32. Seo K., Kim D. pH-dependent hemolysis of biocompatible imidazole-grafted polyaspartamide derivatives. Acta Biomater 2010, 6:2157-2164.
33. Cai G., Zhang H., Liu P., Wang L., Jiang H. Triggered disassembly of hierarchically assembled onion-like micelles into the pristine core-shell micelles via a small change in pH. Acta Biomater 2011, 7:3729-3737.
34. Simoes S., Slepushkin V., Düzgünes N., Pedroso de Lima M.C. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta (BBA)-Biomembr 2001, 1515:23-37.
35. Wang Y.Z., Hao J.G., Li Y.J., Zhang Z.W., Sha X.Y., Han L.M., et al. Poly(caprolactone)-modified Pluronic P105 micelles for reversal of paclitaxcel-resistance in SKOV-3 tumors. Biomaterials 2012, 33:4741-4751.
36. Kopecka J., Campia I., Olivero P., Pescarmona G., Ghigo D., Bosia A., et al. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J Control Release 2011, 149:196-205.
37. Qiu L., Zheng C., Zhao Q. Mechanisms of drug resistance reversal in DOX-resistant MCF-7 cells by pH-responsive amphiphilic polyphosphazene containing diisopropylamino side groups. Mol Pharm 2012, 9:1109-1117.
38. Han M., Diao Y.Y., Jiang H.L., Ying X.Y., Chen D.W., Liang W.Q., et al. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle. Int J Pharm 2011, 420:404-411.
39. ® for tumor-targeted delivery of docetaxel. Biomaterials 2011, 32:7181-7190.
40. Weiszhár Z., Czúcz J., Révész C., Rosivall L., Szebeni J., Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci 2012, 45:492-498.
41. Jun L.H., Xia Y.Q., Li D., Zhong L.J., Ming C.J. Phospholipid-Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel. Drug Dev Ind Pharm 2011, 37:597-605.
42. Noudeh G.D., Khazaeli P., Rahmani P. Study of the effects of polyethylene glycol sorbitan esters surfactants group on biological membranes. Int J Pharmacol 2008, 4:27-33.
43. Yin H.Q., Lee E.S., Kim D., Lee K.H., Oh K.T., Bae Y.H. Physicochemical characteristics of pH-sensitive poly(l-Histidine)-b-poly(ethylene glycol)/poly(l-lactide)-b-poly(ethylene glycol) mixed micelles. J Control Release 2008, 126:130-138.
44. Luo Z.L., Jiang J.W. pH-sensitive drug loading/releasing in amphiphilic copolymer PAE-PEG: integrating molecular dynamics and dissipative particle dynamics simulations. J Control Release 2012, 162:185-193.
45. Johnson R.P., Jeong Y., John J.V., Chung C.-W., Kang D.H., Selvaraj M., et al. Dual stimuli-responsive poly(N-isopropylacrylamide)-b-poly(l-histidine) chimeric materials for the controlled delivery of doxorubicin into liver carcinoma. Biomacromolecules 2013, 14:1434-1443.
46. Liu R., Li D., He B., Xu X.H., Sheng M.M., Lai Y., et al. Anti-tumor drug delivery of pH-sensitive poly(ethylene glycol)-poly(l-histidine-)-poly(l-lactide) nanoparticles. J Control Release 2011, 152:49-56.
47. Lee J.S., Paull K., Alvarez M., Hose C., Monks A., Grever M., et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994, 46:627-638.
48. Ježek P., Plecitá Hlavatá L. Mitochondrial reticulum network dynamics in relation to oxidative stress, redox regulation, and hypoxia. Int J Biochem Cell 2009, 41:1790-1804.
49. Milgram N.W., Racine R.J., Nellis P., Mendonca A., Ivy G.O. Maintenance on l-deprenyl prolongs life in aged male rats. Life Sci 1990, 47:415-420.
50. Li J., Huo M., Wang J., Zhou J., Mohammad J.M., Zhang Y., et al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 2012, 33:2310-2320.
51. Choi K.Y., Min K.H., Yoon H.Y., Kim K., Park J.H., Kwon I.C., et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 2011, 32:1880-1889.
52. Cho H.J., Yoon I.S., Yoon H.Y., Koo H., Jin Y.J., Ko S.H., et al. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials 2012, 33:1190-1200.
53. Zhou B., Weigel J.A., Fauss L., Weigel P.H. Identification of the hyaluronan receptor for endocytosis (HARE). J Biol Chem 2000, 275:37733-37741.
54. Choi K.Y., Saravanakumar G., Park J.H., Park K. Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf B: Biointerfaces 2012, 99:82-94.